Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
23/02/2026 12:27
Feb 23 (Reuters) - Armata Pharmaceuticals Inc ARMP.A: ARMATA PHARMACEUTICALS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) DESIGNATION FOR AP-SA02 ARMATA: PLANS TO ADVANCE AP-SA02 INTO PHASE 3 SUPERIORITY STUDY IN COMPLICATED S. AUREUS BACTEREMIA, ANTICIPATED TO INITIATE IN SECOND HALF OF 2026 Source text: ID:nPn5G15fFa Further company coverage: ARMP.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles